Emergency management of incidental pulmonary embolism (IPE).
Ambulatory care
Anticoagulation
Cancer
Incidental pulmonary embolism
Journal
Emergency cancer care
ISSN: 2731-4790
Titre abrégé: Emerg Cancer Care
Pays: England
ID NLM: 9918434681506676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
02
2022
accepted:
14
04
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
ppublish
Résumé
Venous thrombo-embolic (VTE) disease is a common cause of complications in patients with cancer and is the second most common cause of death in oncology patients other than the malignant disease. Whilst symptomatic VTE comprises the majority of such presentations to an emergency department (ED), incidental pulmonary embolism (IPE) is an increasingly frequent reason for attendance. Many studies report that the consequences of IPE do not differ significantly from those with symptomatic presentations and thus most guidelines recommend using the same approach. The complexity of treatment in cancer patients due to increased prevalence of co-morbidities, higher risk of bleeding, abnormal platelet and renal function, greater risk of VTE recurrence, and medications with the risk of anticoagulant interaction are consistent across patients with symptomatic and IPE. One of the initial challenges of the management of IPE is the design of a pathway that provides both patients and clinicians with a seamless journey from the radiological diagnosis of IPE to their initial clinical workup and management. Increased access to ambulatory care has successfully reduced ED utilisation and improved clinical outcomes in high-risk non-oncological populations, such as those with IPE. In this clinical review, we consider IPE management, its workup, the conundrums it may present for emergency physicians and the need to consider emergency ambulatory care for this growing cohort of patients.
Identifiants
pubmed: 35844667
doi: 10.1186/s44201-022-00004-7
pii: 4
pmc: PMC9207846
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
7Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Ann Intern Med. 2022 Jan;175(1):29-35
pubmed: 34807722
Thromb J. 2018 Feb 06;16:8
pubmed: 29445314
J Thromb Haemost. 2007 Mar;5(3):632-4
pubmed: 17319909
Blood Adv. 2020 Apr 28;4(8):1606-1614
pubmed: 32311012
BMJ Open. 2020 Nov 19;10(11):e040151
pubmed: 33444199
Clin Med (Lond). 2018 Feb;18(1):69-74
pubmed: 29436442
Acta Radiol. 2014 Feb;55(1):45-53
pubmed: 23864061
Eur Respir J. 2017 Jun 29;49(6):
pubmed: 28663318
Thromb Res. 2012 May;129(5):e194-9
pubmed: 22475313
Acute Med. 2020;19(4):201-208
pubmed: 33215173
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33436486
Arch Intern Med. 2010 Aug 9;170(15):1383-9
pubmed: 20696966
Eur Heart J. 2003 Sep;24(18):1651-6
pubmed: 14499227
Int J Clin Pract. 2020 Jan;74(1):e13436
pubmed: 31633264
Support Care Cancer. 2021 Mar;29(3):1293-1302
pubmed: 32621266
J Clin Oncol. 2018 Jul 10;36(20):2017-2023
pubmed: 29746227
Acute Med. 2018;17(3):148-153
pubmed: 30129948
J Clin Oncol. 2011 Jun 10;29(17):2405-9
pubmed: 21555690
Br J Cancer. 2017 Apr 11;116(8):994-1001
pubmed: 28267709
Eur Respir J. 2021 Jul 1;58(1):
pubmed: 33303548
Thromb Res. 2015 Sep;136(3):531-4
pubmed: 26254194
Int J Emerg Med. 2017 Dec;10(1):19
pubmed: 28589462
Res Pract Thromb Haemost. 2019 Oct 21;4(1):154-160
pubmed: 31989097
Eur J Cancer. 2021 Oct 15;158:99-110
pubmed: 34662835
Eur Heart J. 2020 Jan 21;41(4):543-603
pubmed: 31504429
Support Care Cancer. 2016 May;24(5):2129-2137
pubmed: 26556209
Blood Adv. 2021 Feb 23;5(4):927-974
pubmed: 33570602
Eur Respir J. 2020 Feb 6;55(2):
pubmed: 31727694
PLoS One. 2019 Sep 12;14(9):e0222149
pubmed: 31514205
J Clin Oncol. 2020 Feb 10;38(5):496-520
pubmed: 31381464
J Thromb Haemost. 2012 Dec;10(12):2602-4
pubmed: 23362525
Eur Respir J. 2017 Jan 4;49(1):
pubmed: 28052954
J Thromb Haemost. 2020 Feb;18(2):411-421
pubmed: 31630479
N Engl J Med. 2018 Feb 15;378(7):615-624
pubmed: 29231094
J Thromb Haemost. 2021 Nov;19(11):2791-2800
pubmed: 34532927
CJEM. 2015 May;17(3):270-8
pubmed: 26034913
Br J Radiol. 2018 Jul;91(1088):20170806
pubmed: 29688026
J Intern Med. 2007 Jun;261(6):597-604
pubmed: 17547715
N Engl J Med. 2020 Apr 23;382(17):1599-1607
pubmed: 32223112
J Thromb Haemost. 2021 Oct;19(10):2468-2479
pubmed: 34161655
Chest. 2012 Feb;141(2 Suppl):e419S-e496S
pubmed: 22315268
J Clin Oncol. 2019 Jul 10;37(20):1713-1720
pubmed: 31116676
Circ J. 2021 Feb 17;:
pubmed: 33597323
JAMA Intern Med. 2016 Nov 1;176(11):1693-1702
pubmed: 27695822
Ann Emerg Med. 2016 Dec;68(6):712-716
pubmed: 27038693
Support Care Cancer. 2021 Feb;29(2):1129-1138
pubmed: 33230644
J Thromb Haemost. 2015 May;13(5):880-3
pubmed: 25714858
Chest. 2013 Jan;143(1):138-145
pubmed: 22814859
J Thromb Haemost. 2021 Nov;19(11):2751-2759
pubmed: 34260816
Eur Respir Rev. 2019 Mar 27;28(151):
pubmed: 30918022
Support Care Cancer. 2018 Oct;26(10):3601-3607
pubmed: 29725804
J Thromb Haemost. 2016 Jan;14(1):105-13
pubmed: 26469193